Profile data is unavailable for this security.
About the company
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
- Revenue in SEK (TTM)209.08m
- Net income in SEK-72.86m
- Incorporated2008
- Employees26.00
- LocationXbrane Biopharma ABRetzius Vag 8SOLNA 171 65SwedenSWE
- Phone+46 855905600
- Websitehttps://xbrane.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alzinova AB | 205.00k | -26.88m | 122.02m | 5.00 | -- | 0.5965 | -- | 595.20 | -0.2846 | -0.2846 | 0.0022 | 1.23 | 0.0015 | -- | 0.3254 | 41,000.00 | -19.42 | -12.21 | -20.69 | -12.85 | -5,834.15 | -- | -13,114.15 | -21,390.81 | -- | -1,794.80 | 0.0062 | -- | -88.89 | -- | -24.71 | -- | 19.48 | -- |
| SoftOx Solutions AS | 12.76m | -2.82m | 136.35m | 5.00 | -- | 1.34 | 180.23 | 10.68 | -0.001 | -0.001 | 0.0065 | 0.0445 | 0.123 | -- | 30.13 | 2,717,798.00 | -2.72 | -50.91 | -3.22 | -67.07 | -- | -- | -22.07 | -644.92 | 1.16 | -3.92 | 0.1212 | -- | 13.38 | 14.06 | -8.86 | -- | -- | -- |
| NextCell Pharma AB | 10.94m | -35.14m | 159.96m | 24.00 | -- | 2.41 | -- | 14.63 | -0.4414 | -0.4414 | 0.133 | 0.596 | 0.1384 | 51.23 | 4.68 | -- | -44.48 | -34.95 | -49.25 | -37.53 | -155.37 | -266.34 | -321.31 | -427.08 | 9.92 | -- | -- | -- | 2.56 | 25.13 | 16.25 | -- | 36.88 | -- |
| ViroGates A/S | 7.15m | -17.56m | 161.89m | 7.00 | -- | 33.56 | -- | 22.65 | -1.63 | -1.63 | 0.6609 | 0.3665 | 0.3568 | 0.9777 | 4.41 | 504,300.00 | -87.63 | -54.92 | -131.36 | -63.15 | 47.33 | 72.98 | -245.63 | -215.48 | 1.58 | -16.13 | 0.6277 | -- | -12.27 | 6.45 | -18.59 | -- | -- | -- |
| SenzaGen AB | 57.88m | -16.18m | 164.63m | 37.00 | -- | 2.22 | -- | 2.84 | -0.5483 | -0.5483 | 1.96 | 2.52 | 0.5577 | 5.47 | 6.63 | 1,702,294.00 | -15.59 | -20.91 | -18.89 | -25.17 | 65.09 | 67.10 | -27.95 | -71.43 | 2.73 | -- | 0.0707 | -- | 15.69 | 84.16 | 19.22 | -- | -1.18 | -- |
| Oncoinvent ASA | 5.08m | -101.06m | 177.86m | 7.00 | -- | 0.3849 | -- | 35.03 | -176.33 | -176.33 | 8.86 | 109.85 | 0.0354 | -- | 0.4134 | 360,333.30 | -70.49 | -68.76 | -88.81 | -82.93 | -- | -- | -1,990.44 | -40,397.77 | -- | -- | 0.00 | -- | 139.55 | -37.51 | 26.85 | -- | -- | -- |
| Klaria Pharma Holding AB (publ) | 11.23m | -58.70m | 202.68m | 4.00 | -- | 44.60 | -- | 18.04 | -0.4069 | -0.3093 | 0.0699 | 0.0185 | 0.201 | -- | 5.34 | 2,808,250.00 | -105.02 | -48.20 | -649.38 | -74.06 | -- | -- | -522.58 | -1,522.52 | -- | -2.47 | 0.1195 | -- | -73.41 | -11.85 | -33.44 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -16.44m | 203.76m | 2.00 | -- | 4.44 | -- | -- | -0.2729 | -0.2729 | 0.00 | 0.671 | 0.00 | -- | -- | 0.00 | -43.00 | -67.58 | -46.15 | -73.43 | -- | -- | -- | -- | -- | -- | 0.0619 | -- | -- | -- | 53.32 | -- | -- | -- |
| Xbrane Biopharma AB | 209.08m | -72.86m | 206.47m | 26.00 | -- | 0.3517 | -- | 0.9875 | -5.16 | 8.99 | 14.57 | 28.49 | 0.2713 | 0.2899 | 5.00 | 3,216,539.00 | -9.46 | -37.48 | -15.30 | -65.13 | 71.25 | -- | -34.85 | -233.69 | 1.71 | -1.49 | 0.00 | -- | -16.76 | -- | 17.70 | -- | 113.17 | -- |
| Dextech Medical AB | 0.00 | -4.96m | 210.74m | 1.00 | -- | 8.81 | -- | -- | -0.2684 | -0.2684 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -18.58 | -19.36 | -18.94 | -19.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.96 | -- | 40.14 | -- |
| AlzeCure Pharma AB | 0.00 | -39.20m | 218.34m | 11.00 | -- | 4.31 | -- | -- | -0.4047 | -0.4047 | 0.00 | 0.4409 | 0.00 | -- | -- | 0.00 | -71.83 | -73.70 | -88.08 | -83.65 | -- | -- | -- | -- | -- | -- | 0.053 | -- | -- | -- | 5.20 | -- | -38.94 | -- |
| Promimic AB | 45.57m | -12.13m | 223.87m | 18.00 | -- | 3.67 | -- | 4.91 | -0.6388 | -0.6388 | 2.40 | 3.23 | 0.603 | -3.56 | 3.62 | 2,398,421.00 | -16.05 | -20.50 | -18.57 | -24.44 | 105.07 | 104.49 | -26.62 | -59.75 | 3.52 | -- | 0.00 | -- | 18.63 | 50.25 | -36.09 | -- | -- | -- |
| Sprint Bioscience AB | 49.53m | -25.65m | 228.97m | 29.00 | -- | 37.76 | -- | 4.62 | -0.2986 | -0.2986 | 0.5832 | 0.0575 | 1.47 | -- | 6.02 | 1,303,316.00 | -76.04 | -60.40 | -262.43 | -100.72 | 61.94 | 57.87 | -51.79 | -87.25 | -- | -36.01 | 0.00 | -- | 30.02 | 14.37 | -4,072.83 | -- | 69.39 | -- |
| Circio Holding ASA | 0.00 | -8.64m | 236.44m | 9.00 | 9.64 | -- | -- | -- | 0.1348 | 0.1348 | 0.00 | -0.0836 | 0.00 | -- | -- | 0.00 | -93.87 | -47.84 | -- | -58.78 | -- | -- | -- | -6,460.26 | -- | -- | -- | -- | -100.00 | -- | 150.93 | -- | 7.12 | -- |
| Xintela AB | 2.96m | -42.28m | 240.29m | 13.00 | -- | -- | -- | 81.26 | -0.0665 | -0.0665 | 0.0046 | -0.0396 | 0.3486 | -- | 6.47 | 227,461.50 | -498.42 | -194.17 | -- | -651.77 | 100.00 | -- | -1,429.86 | -6,272.93 | -- | -16.40 | -- | -- | 5,303.85 | 156.45 | 27.54 | -- | -- | -- |
| Bio-Works Technologies AB | 41.41m | -29.78m | 277.98m | 29.00 | -- | 7.57 | -- | 6.71 | -0.50 | -0.50 | 0.5878 | 0.3738 | 0.6931 | 0.9866 | 6.45 | 1,380,200.00 | -49.84 | -50.49 | -67.92 | -61.39 | 72.68 | 70.42 | -71.91 | -140.95 | 1.65 | -- | 0.00 | -- | -41.99 | 35.51 | 34.25 | -- | -48.46 | -- |
Data as of Feb 16 2026. Currency figures normalised to Xbrane Biopharma AB's reporting currency: Swedish Krona SEK
2.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 Jan 2026 | 307.77k | 1.49% |
| Swedbank Robur Fonder ABas of 29 May 2024 | 121.64k | 0.59% |
| SEB Funds ABas of 30 Jan 2026 | 93.88k | 0.46% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 17.23k | 0.08% |
| Skandia Investment Management ABas of 28 Nov 2025 | 709.00 | 0.00% |
| Danske Bank A/S (Investment Management)as of 31 Jan 2026 | 523.00 | 0.00% |
| Dimensional Fund Advisors LPas of 30 Nov 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Nov 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
